{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:34:55Z","timestamp":1792294495615,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12954-019-0278-6","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T08:03:32Z","timestamp":1548662612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Medical cannabis patterns of use and substitution for opioids &amp; other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-3842","authenticated-orcid":false,"given":"Philippe","family":"Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Jikomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"issue":"8","key":"278_CR1","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cbdv.200790144","volume":"4","author":"EB Russo","year":"2007","unstructured":"Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614\u201348.","journal-title":"Chem Biodivers"},{"issue":"8","key":"278_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2017.303818","volume":"107","author":"B Fischer","year":"2017","unstructured":"Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107(8):e1\u2013e12.","journal-title":"Am J Public Health"},{"issue":"2","key":"278_CR3","first-page":"13","volume":"2","author":"L Grinspoon","year":"2007","unstructured":"Grinspoon L. On the future of cannabis as medicine. Clin Trials. 2007;2(2):13\u20135.","journal-title":"Clin Trials"},{"issue":"12","key":"278_CR4","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jpain.2015.07.014","volume":"16","author":"MA Ware","year":"2015","unstructured":"Ware MA, Wang T, Shapiro S, Collet J-P. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233\u201342. Available from: \n                    http:\/\/www.jpain.org\/article\/S1526590015008378\/fulltext\n                    \n                  . [cited 2015 Sep 21]","journal-title":"J Pain"},{"issue":"14","key":"278_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1503\/cmaj.091414","volume":"182","author":"MA Ware","year":"2010","unstructured":"Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182(14):1\u20138.","journal-title":"CMAJ"},{"issue":"7","key":"278_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","volume":"68","author":"DI Abrams","year":"2007","unstructured":"Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515\u201321. Available from: \n                    http:\/\/www.neurology.org\/cgi\/doi\/10.1212\/01.wnl.0000253187.66183.9c\n                    \n                   [cited 2017 Feb 6]","journal-title":"Neurology"},{"issue":"1","key":"278_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S1928","volume":"4","author":"EB Russo","year":"2008","unstructured":"Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4(1):245\u201359.","journal-title":"Ther Clin Risk Manag"},{"key":"278_CR8","unstructured":"Kowal MA, Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2010\u20132014. Cannabinoids. 2016;11:1\u201318."},{"issue":"11","key":"278_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2105\/AJPH.2016.303426","volume":"106","author":"JH Kim","year":"2016","unstructured":"Kim JH, Santaella-Tenorio J, Mauro C, Wrobel J, Cerd\u00e0 M, Keyes KM, et al. State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. Am J Public Health. 2016;106(11):2032\u20137. Available from: \n                    http:\/\/ajph.aphapublications.org\/doi\/10.2105\/AJPH.2016.303426\n                    \n                  . [cited 2017 Dec 18]","journal-title":"Am J Public Health"},{"issue":"5","key":"278_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamainternmed.2018.1007","volume":"178","author":"H Wen","year":"2018","unstructured":"Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees. JAMA Intern Med. 2018;178(5):673. Available from: \n                    http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.1007\n                    \n                   [cited 2018 Jun 26]","journal-title":"JAMA Intern Med"},{"issue":"3","key":"278_CR11","doi-asserted-by":"publisher","first-page":"e92816","DOI":"10.1371\/journal.pone.0092816","volume":"9","author":"RG Morris","year":"2014","unstructured":"Morris RG, TenEyck M, Barnes JC, Kovandzic TV. The effect of medical marijuana laws on crime: evidence from state panel data, 1990-2006. PLoS One. 2014;9(3):e92816.","journal-title":"PLoS One"},{"issue":"12","key":"278_CR12","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.2105\/AJPH.2013.301612","volume":"104","author":"DM Anderson","year":"2014","unstructured":"Anderson DM, Rees DI, Sabia JJ. Medical marijuana laws and suicides by gender and age. Am J Public Health. 2014;104(12):2369\u201376. Available from: \n                    http:\/\/ajph.aphapublications.org\/doi\/10.2105\/AJPH.2013.301612\n                    \n                  . [cited 2017 Feb 20]","journal-title":"Am J Public Health"},{"key":"278_CR13","doi-asserted-by":"crossref","unstructured":"Anderson DM, Hansen B, Rees DI. Medical marijuana laws, traffic fatalities, and alcohol consumption. J law Econ 2013;56(2):333\u2013369. Available from: http:\/\/www.econstor.eu\/handle\/10419\/58536%5Cnhttp:\/\/www.jstor.org\/stable\/10.1086\/668812","DOI":"10.1086\/668812"},{"issue":"2","key":"278_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2105\/AJPH.2016.303577","volume":"107","author":"J Santaella-Tenorio","year":"2017","unstructured":"Santaella-Tenorio J, Mauro CM, Wall MM, Kim JH, Cerd\u00e1 M, Keyes KM, et al. US traffic fatalities, 1985-2014, and their relationship to medical marijuana laws. Am J Public Health. 2017;107(2):336\u201342.","journal-title":"Am J Public Health"},{"key":"278_CR15","doi-asserted-by":"crossref","unstructured":"Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ [Internet]. British Medical Journal Publishing Group. 2012;344:e536. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22323502\n                    \n                  . [cited 18 Jan 2019].","DOI":"10.1136\/bmj.e536"},{"issue":"8","key":"278_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2105\/AJPH.2017.303818a","volume":"107","author":"B Fischer","year":"2017","unstructured":"Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107(8):1277. Available from: \n                    http:\/\/ajph.aphapublications.org\/doi\/10.2105\/AJPH.2017.303818a\n                    \n                  . [cited 2018 Mar 1]","journal-title":"Am J Public Health"},{"issue":"10","key":"278_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1158\/1055-9965.EPI-06-0330","volume":"15","author":"M Hashibe","year":"2006","unstructured":"Hashibe M, Morgenstern H, Cui Y, Tashkin DP, Zhang ZF, Cozen W, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomark Prev. 2006;15(10):1829\u201334.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"278_CR18","first-page":"46","volume":"5","author":"MA Morris","year":"2018","unstructured":"Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, et al. Marijuana use Associations with pulmonary symptoms and function in tobacco smokers enrolled in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS). Chronic Obstr Pulm Dis. 2018;5(1):46\u201356. Available from: \n                    https:\/\/journal.copdfoundation.org\/jcopdf\/id\/1177\/Marijuana-Use-Associations-with-Pulmonary-Symptoms-and-Function-in-Tobacco-Smokers-Enrolled-in-the-Subpopulations-and-Intermediate-Outcome-Measures-in-COPD-Study-SPIROMICS\n                    \n                   [cited 2018 Feb 5]","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"2","key":"278_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1183\/09031936.00065707","volume":"31","author":"S Aldington","year":"2008","unstructured":"Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J. 2008;31(2):280\u20136. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18238947\n                    \n                   [cited 2017 Sep 17]","journal-title":"Eur Respir J"},{"issue":"10","key":"278_CR20","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s10552-013-0259-0","volume":"24","author":"RC Callaghan","year":"2013","unstructured":"Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control. 2013;24(10):1811\u201320. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23846283\n                    \n                  . [cited 2017 Sep 17]","journal-title":"Cancer Causes Control"},{"issue":"1","key":"278_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1055-9965.EPI-14-1026","volume":"24","author":"H Y-HJ","year":"2015","unstructured":"Y-HJ H, Zhang Z-F, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. 2015;24(1):15\u201331. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25587109\n                    \n                  . [cited 2017 Sep 17]","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"278_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1513\/AnnalsATS.201212-127FR","volume":"10","author":"DP Tashkin","year":"2013","unstructured":"Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10(3):239\u201347. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23802821\n                    \n                  .[cited 2017 Sep 17]","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"278_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/AOG.0000000000001649","volume":"128","author":"SN Conner","year":"2016","unstructured":"Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG. Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. Obstet Gynecol. 2016;128(4):713\u201323. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27607879\n                    \n                  . [cited 2016 Oct 27]","journal-title":"Obstet Gynecol"},{"issue":"4","key":"278_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ctcp.2009.07.001","volume":"15","author":"RE Westfall","year":"2009","unstructured":"Westfall RE, Janssen PA, Lucas P, Capler R. Reprint of: survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against \u201cmorning sickness.\u201d. Complement Ther Clin Pract. 2009;15(4):242\u20136.","journal-title":"Complement Ther Clin Pract"},{"issue":"3","key":"278_CR25","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1542\/peds.2014-4147","volume":"135","author":"S Ammerman","year":"2015","unstructured":"Ammerman S, Ryan S, Adelman WP, Committee on Substance Abuse, the Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3):e769\u201385. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25624385\n                    \n                  . [cited 2017 Jul 19]","journal-title":"Pediatrics"},{"issue":"6","key":"278_CR26","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0167-6296(01)00102-3","volume":"20","author":"J DiNardo","year":"2001","unstructured":"DiNardo J, Lemieux T. Alcohol, marijuana, and American youth: the unintended consequences of government regulation. J Health Econ. 2001;20(6):991\u20131010. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11758056\n                    \n                  . [cited 2017 Jul 20]","journal-title":"J Health Econ"},{"issue":"5","key":"278_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/00048670801961156","volume":"42","author":"M Cohen","year":"2008","unstructured":"Cohen M, Solowij N, Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry. 2008;42(5):357\u201368.","journal-title":"Aust N Z J Psychiatry"},{"key":"278_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/oxfordjournals.bja.a013457","volume":"84","author":"A Holdcroft","year":"2000","unstructured":"Holdcroft A. Adverse effects of cannabis and cannabinoids. British J Anaesthesia. 2000;84:419\u201320.","journal-title":"British J Anaesthesia"},{"key":"278_CR29","doi-asserted-by":"crossref","unstructured":"Walsh Z, Gonzalez R, Crosby K, Thiessen M, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2016;51:15\u201329.","DOI":"10.1016\/j.cpr.2016.10.002"},{"key":"278_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.aap.2012.07.016","volume":"50","author":"LA Downey","year":"2013","unstructured":"Downey LA, King R, Papafotiou K, Swann P, Ogden E, Boorman M, et al. The effects of cannabis and alcohol on simulated driving: Influences of dose and experience. Accid Anal Prev. 2013;50:879\u201386. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22871272\n                    \n                  . [cited 2017 Jul 26]","journal-title":"Accid Anal Prev"},{"key":"278_CR31","unstructured":"Perreault S. Impaired Driving in Canada, 2015 [Internet]. Ottawa, ON; 2016. Available from: \n                    https:\/\/www150.statcan.gc.ca\/n1\/en\/pub\/85-002-x\/2016001\/article\/14679-eng.pdf?st=iIxKiIZt\n                    \n                  ."},{"issue":"9752","key":"278_CR32","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD, Independent Scientific Committee on Drugs T, Montaner J, Wood E. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558\u201365. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21036393\n                    \n                  . [cited 2017 May 1]","journal-title":"Lancet"},{"key":"278_CR33","unstructured":"Rehm J, Baliunas D, Brochu S, Fischer B, Gnam W, PAtra J, Popova S, Sarnocinska-Hart A, Taylor B. The costs of substance abuse in Canada 2002. Ottawa. p. 2006."},{"key":"278_CR34","unstructured":"Stockwell T, Vallance K, Martin G, Macdonald S, Ivsins A, Chow C, et al. The price of getting high , stoned and drunk in BC: A comparison of minimum prices for alcohol and other psychoactive substances; 2010. p. 1\u20138. Available from: \n                    http:\/\/citeseerx.ist.psu.edu\/viewdoc\/download?doi=10.1.1.688.9654&rep=rep1&type=pdf"},{"issue":"9668","key":"278_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0140-6736(09)60455-4","volume":"373","author":"E Wood","year":"2009","unstructured":"Wood E, Werb D, Marshall BD, Montaner JS, Kerr T. The war on drugs: a devastating public-policy disaster. Lancet. 2009;373(9668):989\u201390.","journal-title":"Lancet"},{"issue":"1","key":"278_CR36","first-page":"35","volume":"6","author":"E Wood","year":"2012","unstructured":"Wood E, McKinnon M, Strang R, Kendall PR. Improving community health and safety in Canada through evidence-based policies on illegal drugs. Open Med. 2012;6(1):35\u201340.","journal-title":"Open Med"},{"issue":"6","key":"278_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.drugpo.2013.08.010","volume":"24","author":"Z Walsh","year":"2013","unstructured":"Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24(6):511. Available from: \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2013.08.010","journal-title":"Int J Drug Policy"},{"key":"278_CR38","doi-asserted-by":"crossref","unstructured":"Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30\u20135.","DOI":"10.1016\/j.drugpo.2017.01.011"},{"key":"278_CR39","doi-asserted-by":"crossref","unstructured":"Bottorff JL, Bissell LJL, Balneaves LG, Oliffe JL, Kang HBK, Capler NR, et al. Health effects of using cannabis for therapeutic purposes: a gender analysis of users\u2019 perspectives. Subst Use Misuse. 2011;46(6):769\u201380.","DOI":"10.3109\/10826084.2010.537732"},{"issue":"4","key":"278_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.drugpo.2008.09.007","volume":"20","author":"P Lucas","year":"2009","unstructured":"Lucas P. Moral regulation and the presumption of guilt in Health Canada\u2019s medical cannabis policy and practice. Int J Drug Policy. 2009;20(4):296\u2013303.","journal-title":"Int J Drug Policy."},{"issue":"4","key":"278_CR41","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.drugpo.2014.02.009","volume":"25","author":"L Belle-Isle","year":"2014","unstructured":"Belle-Isle L, Walsh Z, Callaway R, Lucas P, Capler R, Kay R, et al. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy. 2014;25(4):691. Available from: \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2014.02.009","journal-title":"Int J Drug Policy"},{"key":"278_CR42","volume-title":"Cannabis Market Data","author":"Health Canada Cannabis Market Data","year":"2018","unstructured":"Health Canada Cannabis Market Data Cannabis Market Data. 2018. Available from: \n                    https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/licensed-producers\/market-data.html\n                    \n                  . [cited 2018 Dec 27]"},{"issue":"3","key":"278_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/dar.12323","volume":"35","author":"P Lucas","year":"2016","unstructured":"Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Isle L, Kay R, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev. 2016;35(3):326\u201333.","journal-title":"Drug Alcohol Rev"},{"key":"278_CR44","volume-title":"Canadian Census 2011","author":"StatsCan","year":"2011","unstructured":"StatsCan. Canadian Census 2011. Ottawa: StatsCan; 2011. Available from: \n                    https:\/\/www12.statcan.gc.ca\/census-recensement\/2011\/dp-pd\/prof\/index.cfm?Lang=E"},{"issue":"1","key":"278_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/can.2017.0012","volume":"2","author":"A Reiman","year":"2017","unstructured":"Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: patient self-report. Cannabis Cannabinoid Res. 2017;2(1):160\u20136. Available from: \n                    http:\/\/online.liebertpub.com\/doi\/10.1089\/can.2017.0012\n                    \n                  . [cited 2017 Aug 1]","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"278_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/02791072.2012.684624","volume":"44","author":"P Lucas","year":"2012","unstructured":"Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs. 2012;44(2):125\u201333.","journal-title":"J Psychoactive Drugs"},{"key":"278_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cpr.2016.10.002","volume":"51","author":"Z Walsh","year":"2017","unstructured":"Walsh Z, Gonzalez R, Crosby KS, Thiessen M, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15\u201329.","journal-title":"Clin Psychol Rev"},{"issue":"1\u20133","key":"278_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2010.04.007","volume":"120","author":"P DeRosse","year":"2010","unstructured":"DeRosse P, Kaplan A, Burdick KE, Lencz T, Malhotra AK. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res. 2010;120(1\u20133):95\u2013100.","journal-title":"Schizophr Res"},{"issue":"6","key":"278_CR49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/JCP.0000000000000581","volume":"36","author":"MA Katzman","year":"2016","unstructured":"Katzman MA, Furtado M, Anand L. Targeting the endocannabinoid system in psychiatric illness. J Clin Psychopharmacol. 2016;36(6):691\u2013703. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27811555\n                    \n                  . [cited 2018 Aug 28]","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"278_CR50","doi-asserted-by":"publisher","first-page":"e0157060","DOI":"10.1371\/journal.pone.0157060","volume":"11","author":"KA Sagar","year":"2016","unstructured":"Sagar KA, Dahlgren MK, Racine MT, Dreman MW, Olson DP, Gruber SA. Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. Hashimoto K, editor. PLoS One. 2016;11(6):e0157060. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27275781\n                    \n                  . [cited 2018 Oct 29]","journal-title":"PLoS One"},{"key":"278_CR51","volume-title":"State of the evidence; cannabis use and regulation","author":"D Werb","year":"2015","unstructured":"Werb D, Watson TM, Maghsoudi N. State of the evidence; cannabis use and regulation; 2015."},{"key":"278_CR52","unstructured":"Boyd S. Drug use, arrests, policing, and imprisonment in Canada and BC, 2015\u20132016. Vancouver; 2018. Available from: \n                    https:\/\/drugpolicy.ca\/wp-content\/uploads\/2018\/03\/Vandu-Report-Mar-9-2018.pdf\n                    \n                  . [cited 2018 Sep 11]"},{"key":"278_CR53","unstructured":"Opioid-Related Harms in Canada. Ottawa; 2017 Available from: \n                    www.cihi.ca\n                    \n                  . [cited 2018 Sep 11]"},{"key":"278_CR54","doi-asserted-by":"crossref","unstructured":"Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for medicaid enrollees. Health Aff 2017;36(5):945\u2013951. Available from: \n                    http:\/\/www.healthaffairs.org\/doi\/10.1377\/hlthaff.2016.1135\n                    \n                  . [cited 2018 Jun 13]","DOI":"10.1377\/hlthaff.2016.1135"},{"issue":"1","key":"278_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12954-017-0183-9","volume":"14","author":"P Lucas","year":"2017","unstructured":"Lucas P. Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduct J. 2017;14(1):58. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28821296\n                    \n                  . [cited 2017 Aug 22]","journal-title":"Harm Reduct J"},{"issue":"6","key":"278_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jpain.2016.03.002","volume":"17","author":"KF Boehnke","year":"2016","unstructured":"Boehnke KF, Litinas E, Clauw DJ, Arnold LM, Clauw DJ, Dunegan LJ, et al. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739\u201344. Available from: \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590016005678\n                    \n                  . [cited 2017 Feb 6]","journal-title":"J Pain"},{"issue":"3","key":"278_CR57","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/dar.12667","volume":"37","author":"H Reddon","year":"2018","unstructured":"Reddon H, DeBeck K, Socias ME, Dong H, Wood E, Montaner J, et al. Cannabis use is associated with lower rates of initiation of injection drug use among street-involved youth: a longitudinal analysis. Drug Alcohol Rev. 2018;37(3):421\u20138. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29430806\n                    \n                  . [cited 2018 Apr 2]","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"278_CR58","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1521-0391.2013.12044.x","volume":"22","author":"JL Scavone","year":"2013","unstructured":"Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ. Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict. 2013;22(4):344\u201351.","journal-title":"Am J Addict"},{"key":"278_CR59","first-page":"301","volume-title":"Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence","author":"WN Raby","year":"2009","unstructured":"Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, et al. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence; 2009. p. 301\u20138."},{"issue":"12","key":"278_CR60","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1111\/add.14398","volume":"113","author":"ME Soc\u00edas","year":"2018","unstructured":"Soc\u00edas ME, Wood E, Lake S, Nolan S, Fairbairn N, Hayashi K, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250\u20138. Available from: \n                    http:\/\/doi.wiley.com\/10.1111\/add.14398\n                    \n                  . [cited 2018 Dec 28]","journal-title":"Addiction"},{"issue":"3","key":"278_CR61","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES) | Eysenbach | Journal of Medical Internet Research. J Med Internet Res. 2004;6(3):e34. Available from: \n                    http:\/\/www.jmir.org\/2004\/3\/e34\n                    \n                  \/","journal-title":"J Med Internet Res"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0278-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0278-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0278-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T19:13:35Z","timestamp":1580152415000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0278-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0278-6","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"7 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This survey was ethics reviewed and approved by Advarra (formerly Institutional Review Board Services; reference # Pro00018492), and the University of Victoria subsequently approved a post-survey sub-analysis of the substitution data (reference # 17-188). A password-protected link to an online survey available in French and English was sent out to 16,675 Tilray patients in January 2017. Clicking on the link in the email invitation took patients to the IRB approved Informed Consent Form (ICF), and consent was gathered electronically.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This research was supported by Tilray, a federally authorized Canadian medical cannabis production and research company. PL is Global Vice-President, Patient Research and Access for Tilray (\n                      \n                      ), and he designed the survey. Formal analysis was conducted by EB, who has no conflict to disclose. Preliminary data analysis was conducted by NJ, Senior Science Advisor, Data & Analytics, at Leafly, an online cannabis website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"9"}}